Nitric oxide (NO) is thought to play an important role in neurotransmission, in¯ammation, and regulation of cell death in the mammalian brain. Here, we examined the synthesis and biological eects of NO in human malignant glioma cells. Exposure to cytokines such as interferon (IFN)-g, tumor necrosis factor (TNF)-a or interleukin (IL)-1b and lipopolysaccharide (LPS) induced NO synthesis in rat C6 and A172 human glioma cells, but not in LN-229, T98G or LN-18 human malignant glioma cells. Induced release of NO involved enhanced expression of inducible NO synthase (iNOS). Failure to detect NO release in the latter cell lines was not overcome by neutralization of endogenous TGF-b or by coexposure to cytokines, LPS, and antioxidants. Apoptosis induced by CD95 ligand (CD95L) did not involve NO formation. Neither NOS inhibitors nor NO donators modulated CD95L-induced apoptosis. Dexamethasone (DEX)-mediated protection of glioma cells from CD95L-induced apoptosis was also independent of DEX eects on NO metabolism. DEX inhibited not only cytokine/ LPS-evoked NO release but also attenuated the toxicity of NO in three of ®ve cell lines. Forced expression of temperature-sensitive p53 val 135 in C6 cells in either mutant or wild-type conformation inhibited cytokine/LPS-induced NO synthesis. Further, accumulation of p53 in both mutant or wild-type conformation protected glioma cells from the toxicity of exogenous NO, consistent with a gain of p53 function associated with p53 accumulation. We conclude that resistance to NO-dependent immune defense mechanisms may contribute to the malignant progression of human cancers with p53 alterations, notably those associated with the accumulation of mutant p53 protein.
Introduction
Nitric oxide (NO) has many physiological and pathophysiological eects on neuronal and nonneuronal cells of the central nervous system. NO is formed from L-arginine by at least three dierent types of NO synthases (NOS). Brain and endothelial NOS are constitutively expressed, calcium-dependent, and produce only small amounts of NO. These levels of NO have signalling functions mediated by cGMP. Another type of NOS is induced, e.g., by cytokines. Inducible NOS (iNOS) is calcium-independent and produces large amounts of NO which may mediate cGMP-independent cytotoxicity against microorganisms and tumor cells (Stuehr and Nathan, 1989) . iNOS is found in a variety of cells such as macrophages (Marletta et al., 1988) , endothelial cells (Kilbourn and Belloni, 1990 ) and glial cells . While all three types of NOS may be expressed in astrocytomas (Cobbs et al., 1995) , expression of iNOS was only observed in high-grade tumors and mainly restricted to endothelial cells within the tumor. However, expression of iNOS in high-grade gliomas may have been underestimated since most patients have probably been exposed to high doses of steroids prior to tumor resection. Such drugs decrease NO production by inhibiting iNOS expression (Radomski et al., 1990) . Further, high-grade gliomas produce TGF-b , a cytokine known to inhibit NOS activity and NOS expression by reducing iNOS mRNA translation in macrophages (Vodovotz et al., 1993) and in endothelial cells (Murata et al., 1995) . Detection of iNOS mRNA by polymerase chain reaction (PCR) in malignant gliomas (Ellie et al., 1995) is less conclusive since the cellular source remains obscure. While rat C6 glioma cells have been shown to activate iNOS when exposed to appropriate stimuli such as cytokines and LPS by many authors (Simmons and Murphy, 1992; Vigne et al., 1993; Feinstein et al., 1994 ) data on human glioma cells are controversial (Bernatowicz et al., 1995; Fujisawa et al., 1995) .
NO has been shown to induce apoptosis in a variety of cells such as macrophages (Albina et al., 1993) , thymocytes (Fehsel et al., 1995) and chondrocytes (Blanco et al., 1995) . NO-induced apoptosis may involve a p53-dependent pathway (Messmer et al., 1994; Forrester et al., 1996; Ho et al., 1996) . However, iNOS expression may be under negative regulatory control of p53 (Forrester et al., 1996) .
Apoptosis of human malignant glioma cells can be induced by exposure to agonistic antibodies to the cytokine receptor, CD95, or exposure to the natural CD95 ligand (CD95L) (Weller et al., 1994 (Weller et al., , 1995b Wagenknecht et al., 1997a) . Here, we characterized NO synthesis and biological eects of exogenous NO in these cells and asked whether NO plays a role in CD95-mediated apoptosis of glioma cells. Rationales for this study included the following observations: (i) CD95-mediated apoptosis is potentiated by cytokines such as IFN-g and TNF-a (Weller et al., 1994) which also induce NO release (Kilbourn and Belloni, 1990),
(ii) CD95-mediated apoptosis is inhibited by DEX (Weller et al., 1994) , a drug that prevents iNOS activation (Wu et al., 1995; Radomski et al., 1990) , (iii) NO enhances CD95 expression in vascular smooth muscle cells (Fukuo et al., 1996) .
Results
Cytokines and LPS induce iNOS expression and NO synthesis in C6 and A172, but not LN-18, LN-229 or T98G, glioma cell lines
The glioma cells were exposed to a cocktail of IFN-g (100 U/ml), TNF-a (10 ng/ml), IL-1b (2 ng/ml) and LPS (10 mg/ml) for 24 h and nitrite levels determined thereafter (Table 1 ). C6 cells produced signi®cant levels of nitrite. Of the human glioma cell lines, only A172 cells showed nitrite formation. The amount of NO produced by A172 cells was less than 10% of that produced by C6 cells. Neither cytokine alone nor any combination tested had adverse eects on the viability or growth of C6 and LN-229 cells. Growth of T98G and, to a lesser extent, of A172 was inhibited by the cytokines but viability was unaected. Up to 60% of LN-18 cells were killed by the cytokine/LPS cocktail. Immunoblot analysis con®rmed that iNOS expression was induced in C6 and A172 cells but not in the other cells ( Figure 1a) . NO release and induction of iNOS immunoreactivity by cytokines and LPS were abolished by coexposure to cycloheximide (10 mg/ml) (data not shown).
Neutralization of endogenous TGF-b fails to enhance basal and stimulus-evoked NO synthesis Active and total, including both active and latent, TGF-b levels were detected in the medium of all cell lines (Figure 1b) . TGF-b synthesis was lowest in C6 and A172 cells which produced NO in response to the proin¯ammatory cytokines and LPS (Table 1) . We next asked whether neutralization of endogenous TGF-b levels results in enhanced constitutive or stimulusevoked NO production ( Figure 1c ). Nitrite release was neither enhanced in nitrite-releasing cell lines (C6, A172) nor induced in cell lines T98G, which were not induced to release NO in the absence of TGF-b antibodies. When C6 cells were exposed to cytokines and LPS in the presence of TGF-b-containing supernatants of LN-229 or T98G cells, diluted 1 : 2, there was no decrease of nitrite levels, suggesting that the amount of active TGF-b produced by LN-229 or T98G cells is insucient to prevent iNOS expression. This prompted us to check whether induced NO release in the glioma cells was essentially refractory to TGF-bmediated inhibition. In fact, even excessive amounts of exogenous TGF-b (20 ng/ml) added 2 h prior to the cytokine/LPS cocktail failed to modulate cytokine/ LPS-evoked NO release in C6 glioma cells (data not shown). In contrast to chondrocytes (Blanco et al., 1995) , neither LN-229 nor T98G nor LN-18 cells were induced to release NO in the presence of DMSO (0.5%) or N-acetylcysteine (500 mM) (data not shown). However, preexposure for 24 h to DEX (100 nM) signi®cantly reduced nitrite formation of cytokine/ LPS-stimulated C6 cells under all conditions summarized in Table 1 except the combination of all three cytokines and LPS (Figure 1d ).
CD95L-induced glioma cell apoptosis is attenuated by DEX but unaected by NOS inhibitors or NO donators CD95L killed all human glioma cell lines eectively but did not reduce viability of C6 cells. Inhibition of protein synthesis by cycloheximide was required to Table 1 . Soluble protein was harvested at 0, 2, 6 or 24 h after treatment and immunoblot analysis for iNOS performed as described in sensitize A172 and LN-229 to apoptosis (Figure 2a) . DEX conferred signi®cant protection from CD95L-induced apoptosis to all cell lines (Figure 2b ). CD95L-induced cytotoxicity of all cell lines was unaected by the NOS inhibitors, L-NAME and L-NMMA ( Figure  2c ). CD95L itself did not induce NO production in any cell line when administered alone and, in contrast to TNF-a did not enhance NO release induced by LPS or the cytokines (Figure 2d ). NO donators did not modulate CD95-mediated apoptosis of LN-18 cells (Figure 2e ) or any other cell line. Similarly negative results were obtained with SNP pretreatment or posttreatment at 2 or 6 h or when SIN-1 was used instead of SNP. Appropriate control experiments were performed to illustrate that the NO donators released sucient NO to be detected by the Griess assay. for 24 h and then exposed to CD95L (LN-229, 160 U/ml; T98G, 20 U/ml; LN-18, 10 U/ml) or neo control supernatant. Viability was assessed by crystal violet assay. Data are expressed as mean percentages and s.e.m. (n=3) compared with untreated or DEX-pretreated cells with subsequent exposure to neo control supernatant instead of CD95L (*P50.05, **P50.005, t-test). DEX alone had no in¯uence on viability but was moderately mitogenic for T98G but antiproliferative for LN-229 cells . (c) LN-18 glioma cells were treated with increasing concentrations of CD95L in the absence or presence of the NOS inhibitors, L-NMMA (1 mM) or L-NAME (1 mM) for 16 h. Viability was assessed as in a. (d) In the left panel, C6 glioma cells were treated with LPS in the presence of neo control supernatant (open bars) or CD95L (80 U/ml) (grey bars) or TNF-a (10 ng/ml) (black bars). In the right panel, A172 cells were treated with IFN-g (100 U/ml), TNF-a (10 ng/ml), IL-1b (2 ng/ml) and LPS (10 mg/ml) in the presence of neo control supernatant (open bars) or CD95L (80 U/ ml) (black bars). NO release was measured using the Griess assay. Data are representative means and s.e.m. (n=3) (*P50.05, t-test) (e) LN-18 cells were treated with dierent concentrations of CD95L in the presence of increasing concentrations of SIN-1. Viability was assessed as in a. (f) LN-229 cells were either untreated or exposed to IFN-g (100 U/ml) in the absence or presence of L-NMMA (1 mM). CD95 expression was assessed by¯ow cytometry (Weller et al., 1994 ) (open curves, isotype control antibody, ®lled curves, CD95 antibody) 
The glioma cells were either untreated or exposed to IFN-g (100 U/ml), TNF-a (10 ng/ml), IL-b (2 ng/ml) or LPS (10 mg/ml), or combinations thereof, for 24 h. Viability was assessed by crystal violet assay. NO release was measured using the Griess assay. Data are expressed as mean percentages and s.e.m. of survival or means and s.e.m. of nitrite in mM (n=3) Further, NO did not enhance CD95 expression in LN-229 cells (data not shown). In contrast, IFN-g as a positive control readily enhanced CD95 expression (Weller et al., 1994) . This eect was unaected by L-NMMA ( Figure 2f ). There was thus no apparent relation between CD95L-induced apoptosis, NO, and antiapoptotic actions of DEX.
NO-induced apoptosis of human malignant glioma cells: modulation by DEX and cycloheximide
High concentrations of SNP were toxic to the glioma cells. Acridine orange staining revealed features of apoptotic cell death in SNP-treated glioma cells ( Figure  3a ). There was no major dierence in the susceptibility Figure 4a ). There was no dierence in NO sensitivity between p53 wildtype and p53 mutant cell lines (Figure 3b ). To further examine the role of p53 for NO synthesis and NO toxicity in glioma cells, we transfected LN-229, LN-18 and C6 cells with an expression plasmid encoding the temperature-sensitive p53 val 135 mutant that assumes mutant conformation at 38.58C and wild-type conformation at 32.58C (Michalowitz et al., 1990; Trepel et al., 1996; Wagenknecht et al., 1997b) . Strong p53 transgene expression was con®rmed by immunoblot analysis as described . Both pooled cells and single clones obtained by limiting dilution cloning were used for the experiments. Since there were no dierences in biological responses among single clones and high transgene expression throughout the pooled population, the results reported here are those obtained with the pooled transfected cells. First, we examined the eect of forced p53 expression on iNOS expression and NO release triggered by cytokines and LPS. NO release was almost completely blocked in p53-transfected cells in a conformation-independent manner (Figure 4b and c) . Attenuation of NO release was due to the inhibition of iNOS induction by p53 at both temperatures (data not shown). Second, we examined the eect of forced p53 expression on NO toxicity. Mutant p53 (38.58C) protected C6 cells from the toxic eects of NO (Figure 5a ). This protective eect of mutant p53 was attenuated by cycloheximide. Wild-type p53 (32.58C) almost completely blocked SNP toxicity, compared with hygro control cells, both in the absence or presence of cycloheximide. Essentially the same results were obtained in LN-229 cells (data not shown). The dierential eect of cycloheximide on p53-mediated protection in mutant or wild-type conformation was unexpected in that transcriptional activation of p53 target genes is central in considering p53 val 135 wild-type at 32.58C but not 38.58C. Therefore, we next determined the stability of p53 transgene levels at both temperatures. Figure 5c shows that the levels of p53 were rather stable in the presence of cycloheximide within the time frame of the experiments. Since forced expression of p53 val 135 inhibited NO toxicity in p53 mutant LN-18 cells, too (data not shown), dominant negative actions are unlikely to account for the inhibition of NO toxicity by p53 val 135 (Figure 5a ) at 38.58C. At 32.58C, p53 val 135 induced complete growth arrest of the human glioma cells, preferably in G2/M (Figure 6a and b) . In contrast, p53 val 135 failed to inhibit cell cycle progression in rat C6 cells (Figure 6c  and d) . Figure 4 p53 val 135 blocks cytokine/LPS-induced NO release in a conformation-independent manner. (a) LN-229 cells were exposed to SNP (250 mM) for 0, 2, or 24 h and immunoblot analysis performed as described in Materials and methods. LN-229 cells exposed to 2 mM camptothecin for 24 h served as positive control (Weller et al., 1997c) . (b,c) Hygro control or p53-transfected C6 cells were adapted to the respective temperature for 4 h (b, 38.58C; c, 32.58C) and then untreated or exposed to LPS (10 mg/ ml), IL-1b (2 ng/ml), to IFN-g (100 U/ml) plus TNF-a (10 ng/ml) plus LPS (10 mg/ml), or to this cocktail plus IL-1b for 24 h at 38.58C ( Figure 5B ) or 32.58C ( Figure 5C ). Nitrite in the supernatant was determined using the Griess assay. Data are representative and are expressed as means and s.e.m. (n=3) (*P50.05, **P50.0001, t-test) NO 
Discussion
The present study examined the regulation of iNOS activity and NO release in human malignant glioma cells (Figures 1 and 2) , the role of NO in CD95-mediated apoptosis (Figure 3) , and the role of p53 for the synthesis and the biological eects of NO in malignant glioma cells (Figures 4 ± 6 ). While we con®rm rat C6 (Feinstein et al., 1994) and human A172 cells (Fujisawa et al., 1995) to express iNOS and release NO in response to cytokines and LPS, several other glioma cells were refractory to iNOS induction (Table 1, Figure 1 ). Lack of iNOS induction was not caused by endogenous TGF-b release (Figure 1c) . Further, addition of exogenous TGF-b did not inhibit induced NO synthesis in C6 cells, indicating that the TGF-b-signalling pathway might be disrupted in these cells, similar to many other tumor cell lines. Failure to activate iNOS and produce NO in response to in¯ammatory mediators such as IFN-g or TNF-a in the glioma cells might be viewed as a sign of dedierentiation or as well as a pathway to escape immune-mediated tumor attack. However, the concentrations of exogenous NO required to kill glioma cells (Figure 3b ) exceed those produced in cytokine/LPStreated C6 and A172 cells whose viability was unaected by endogenous iNOS activity ( Table 1 ), indicating that glioma should be considered resistant to physiologically occuring concentrations of NO. The induction of iNOS expression in hypoxic tumor tissue may result in the emergence of clonal tumor cell populations that resist iNOS induction per se or the toxic eects of iNOS induction (Kawase et al., 1996) . Prevention of iNOS induction and NO release ( Figure  1d ) and inhibition of NO toxicity (Figure 3c ) add to accumulating evidence that DEX has profound cytoprotective eects in malignant glioma cells (Weller et al., 1994 . To our knowledge, this is the ®rst report to describe direct inhibition of NO toxicity by DEX independent of eects on iNOS activity. Interestingly, there are probably multiple pathways of DEX-mediated cytoprotection since DEX blocks NO toxicity and CD95L-induced apoptosis of T98G cells rather eciently (Figure 2b ) but has little eect on cytotoxic drug eects in these cells . This is an important ®nding in light of the current clinical practice to treat glioma patients with steroids for control of edema and mass eect even during proapoptotic therapy such as irradiation and chemotherapy.
Although both CD95L-and NO-induced apoptosis were inhibited by DEX, there were dierences in the apoptotic cascade as concerns the eects of concurrent inhibition of macromolecular synthesis. While potentia- Figure 5 p53 protects C6 cells from NO toxicity in a conformation-independent manner. (a,b) Hygro (circles) or p53-transfected (triangles) C6 cells were exposed to SNP in the absence (®lled symbols) or presence (open symbols) of cycloheximide (CHX) (10 mg/ml) for 16 h at 38.58C (a) or 32.58C (b). Viability was assessed by crystal violet assay. Data are expressed as mean percentages and s.e.m. (n=3) compared with untreated or cycloheximide-treated controls. Note that NO toxicity is generally more prominent at 38.58C, and less prominent at 32.58C, compared with 378C ( Figure 3c ). (c) p53 transfected C6 cells were exposed to cycloheximide (10 mg/ml) for 0, 1, 3 or 9 h at 38.58C or 32.58C and immunoblot analysis for p53 performed as described in Materials and methods NO, p53 and malignant glioma J Rieger et al tion by actinomycin D or cycloheximide is a typical feature of CD95-mediated apoptosis (Yonehara et al., 1989; Weller et al., 1994) , the eects of these agents on NO toxicity of glioma cells were heterogeneous ( Figure  3c ). NO toxicity was inhibited by cycloheximide in two of three cell lines lacking wild-type p53 function, T98G and LN-18, but not A172, but augmented (C6) or unaected (LN-229) in cell lines carrying wild-type p53. The accumulation of p53 in response to NO exposure, which is blocked by cycloheximide (data not shown), is therefore not required for NO toxicity in C6 and LN-229 cells and may even be protective in C6 cells. In general, wild-type p53-containing cells were not more sensitive to NO toxicity than p53 mutant cell lines (Ho et al., 1996) . In contrast to other cytokines, CD95L does not induce iNOS expression or NO synthesis (Figure 2d ) and CD95L-induced apoptosis is unaected by NOS inhibitors or NO donators (Figure 2c and e) . Given the essential role of CPP-32 activation in CD95-mediated apoptosis, this was surprising in light of a recent report on NO-mediated inhibition of CPP-32 and cytoprotection in endothelial cells (Dimmeler et al., 1997) . Although DEX prevents iNOS expression and NO production in J774.2 macrophages (Wu et al., 1995) , endothelial cells (Radomski et al., 1990) , primary astrocytes (Bernatowicz et al., 1995) and C6 glioma cells exposed to IFN-g, TNF-a and LPS  Figure 1d ), inhibition of CD95-mediated glioma cell apoptosis by DEX (Figure 2b ) is independent of suppression of NO production since LN-229, T98G and LN-18 cells do not produce detectable amounts of NO, neither after exposure to cytokines/LPS nor to CD95L. Thus, in contrast to an increasing number of other biological processes in the immune and nervous system, there is probably no role for NO in glioma cell apoptosis triggered by CD95L.
Recent evidence suggests that the iNOS gene is a target for negative transcriptional regulation by p53 (Forrester et al., 1996) . Consistent with this hypothesis, we show here that forced expression of p53 prevents cytokine/LPS-induced iNOS induction and NO release (Figure 4) . In contrast to the human p53 his 175 mutant (Forrester et al., 1996) , the murine p53 val 135 mutant in its presumptive mutant conformation had a similar inhibitory eect on iNOS gene activation. Further, we ®nd that p53 val 135 blocks NO toxicity in a conformation-independent manner ( Figure 5 ).
Wild-type in the context of temperature-sensitive p53 mutants is commonly de®ned by antiproliferative eects, suppression of transformation, lack of p53/ hsc70 complex formation, pAb1620 immunoreactivity, reporter gene transcription, and transcriptional target gene activation, e.g., of p21 and bax genes (Michalowitz et al., 1990; Trepel et al., 1997) . Growth arrest, pAb1620 immunoreactivity, and enhanced p21 expression were observed in p53 val 135 -transfected glioma cells speci®cally at the permissive temperature (32.58C) in our hands in human glioma cells (Trepel et al., 1996) but not in rat C6 glioma cells (Figure 6 ). The eects of p53 val 135 at 32.58C (Figures 4c and 5c ) are therefore independent of p53-induced growth arrest.
At restrictive temperature (38.58C), p53 val 135 has been reported to act as a transdominant negative p53 mutant (Harvey et al., 1995; Ewen et al., 1995) . We have con®rmed that p53 val 135 blocks camptothecininduced p21 accumulation in LN-229 cells, consistent with transdominant negative inhibition of endogenous p53 (data not shown). However, negative dominance of p53 val 135 was presumably not the mechanism underlying prevention of iNOS expression and NO release triggered by cytokines and LPS since these agents do not induce p53 activity (data not shown) and since iNOS induction is not dependent on wildtype p53 activity as iNOS can be induced in cancer cell lines lacking wild-type p53 (Forrester et al., 1996) . Recently, NO has been suggested to induce a conformational change of p53 from wild-type to mutant (Calmels et al., 1997) . If p53-mediated inhibition of iNOS expression was strictly wild-typespeci®c, the negative feedback loop of NO production and p53 activation would be predicted to be ineective since NO could disrupt this loop by changing the conformation of p53.
Negative dominance can also not account for protection from NO toxicity mediated by p53 val 135 at 38.58C since not only wild-type cells (C6, LN-229) but also p53 mutant cells (LN-18) were protected by p53 val 135 . Rather, the eects of p53 on iNOS expression and NO toxicity display features of a gain of function linked to p53 protein accumulation.
The mechanisms underlying p53-mediated inhibition of iNOS induction and the cytoprotective eects from NO toxicity at both temperatures remain obscure. That no transcriptional activity of p53 val 135 has been identi®ed at 38.58C, does not prove its absence. Transcription-independent eects of p53 have been identi®ed (Caelles et al., 1994; Haupt et al., 1995) but have been proapoptotic rather than cytoprotective. The val 135 mutation aects the DNA binding domain of p53 which is folded independently (Levine, 1997) . We conclude that p53-mediated transcriptional repression of the iNOS promoter may require p53 domains other than those required for transcriptional activition of target genes such as p21 or bax. These domains may be functional in p53 val 135 at 38.58C. This hypothesis gains support from the characterization of negative transcriptional regulatory in¯uences of p53 both in the N-terminus (Liu et al., 1993) and Cterminus (Horikoshi et al., 1995) . That the ability of mutant p53 to repress transcription might be lower than that of wild-type p53 (Seto et al., 1992) , could underlie the lack of iNOS gene repression by a human p53 mutant in a preceding study (Forrester et al., 1996) . Also, species dierences might account for apparent discrepancies between this work and the preceding study (Forrester et al., 1996) . Further, these authors used transient p53 expression which might result in lower levels of mutant p53 than in the stably transfected cell lines used here. Eventually, the experiments with mutant p53 were performed with an iNOS promotor construct which is not inducible by cytokines whereas we assessed the regulation by wildtype or mutant p53 of endogenous cytokine-inducible iNOS activity.
Similarly, p53 domains other than the DNA binding domain, which are unaected by the switch from 38.58C to 32.58C, could be responsible for the eects of p53 val 135 on NO toxicity. NO-dependent tumor cell toxicity could therefore drive a selection process that would favour the emergence of tumor cell clones accumulating p53. Taken together, our data ( Figures  5 and 6 ) de®ne a novel regulation of NO synthesis and NO toxicity by p53 that may have broad implications for cancerogenesis and in¯ammatory processes.
Materials and methods

Materials
methyl-ester (L-NAME), sodium nitroprusside (SNP), LPS (E. coli serotype 0127 : B8), DEX, actinomycin D and cycloheximide were purchased from Sigma (Deisenhofen, Germany), IFN-g, TNF-a and IL-1b from Boehringer (Mannheim, Germany), neutralizing pan-TGF-b antibody from R&D (Wiesbaden, Germany), and 3-morpholinosydnonimine (SIN-1) from Tocris Cookson (Langford, UK).
Cell culture
T98G human and C6 rat malignant glioma cells were obtained from the American Type Culture collection (Rockville, MD). A172, LN-18 and LN-229 human malignant glioma cells were kindly provided by Dr N de Tribolet (Lausanne, Switzerland). The glioma cell lines were cultured in DMEM (Gibco, Scotland) containing 10% FCS and 1% penicilline/streptomycine (Weller et al., 1994 (Weller et al., , 1995a . Viability was assessed by crystal violet staining in 96 well plates. Brie¯y, 10 000 cells per well were seeded and treated as described. The cell culture medium was removed and viable cells stained with 0.5% crystal violet in 20% methanol for 20 min. The plates were extensively washed, dried for 24 h and 50 ml of 0.1 M sodium citrate solution diluted in a 50% water/50% ethanol solution per well added before optical density (OD) was measured at 550 nM in a Titertek Multiskan Plus (Flow Laboratories, Meckenheim, Germany).
Immunoblot analysis
The cells were lysed in lysis buer containing 50 mM TrisHCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 100 mg/ml phenylmethylsulfonyl¯uoride, 10 mg/ml leupeptin and 2 mg/ml aprotinin. After 15 min on ice, the lysates were centrifuged for 10 min at 13 000 r.p.m. The soluble supernatant fraction was used for immunoblot analysis. Protein concentrations were measured by Biorad assay. For gel electrophoresis, 20 mg protein were loaded per lane and separated on 8% or 12% gels for the detection of iNOS or p53, respectively. The proteins were electroblotted to nitrocellullose. The membranes were blocked and incubated overnight with the ®rst antibody. After three washes in PBS containing 0.05% Tween 20, the membranes were incubated with secondary alkaline phosphataseconjugated antibody for 1 h, washed three times in PBS, and stained with nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate in 0.1 M Tris HCl pH 9.5 containing 50 mM MgCl 2 and 10 mM NaCl. Human p53 was detected using a monoclonal antibody to human p53 (AB-6, clone DO-1) and murine p53 using a monoclonal pan-speci®c p53 antibody (AB-3, clone PAb 240, both from Oncogene Science, Cambridge, MA). Rodent and human iNOS were visualized using the polyclonal antibodies C-19 and M-19 from Santa Cruz (California, USA).
Measurement of nitrite concentrations
100 ml aliquots of supernatant were incubated with an equal volume of the Griess reagent (1% sulfanilamide/ 0.1% naphthylethylenediamine dihydrochloride/2.5% H 3 PO 4 ) at room temperature for 10 min. Absorbance was measured at 550 nM in a Titertek Multiskan Plus (Flow Laboratories, Meckenheim, Germany). Values of NO 2 7 were determined using sodium nitrite as a standard.
Production of soluble CD95L
N2A murine neuroblastoma cells were transfected with the BCMGS-murine CD95L expression plasmid (Rensing-Ehl et al., 1995; Roth et al., 1997) . N2A cells were cultured in MEM-Earle medium containing 10% FCS, 1% penicillin/ streptomycine, 1% glutamine and 1% non-essential amino acids. Selection was carried out by adding G418 (0.5 mg/ ml). For CD95L production, medium was removed from con¯uent cell cultures and replaced with serum-free medium lacking G418. After 24 h, the medium from several¯asks was pooled, centrifuged for 5 min at 1200 r.p.m. to remove detached cells and debris and the supernatant was tested for CD95L bioactivity using the highly sensitive LN-18 glioma cell line. 10,000 LN-18 cells per well were grown in 96 well plates for 24 h. Medium was removed and cells exposed to serial dilutions of supernatant from CD95L-transfected N2A or neo control N2A cells. After 24 h, viability was assessed by crystal violet staining. The amount of CD95L, diluted in 100 ml medium, that killed 50% of the cells was de®ned as one unit.
TGF-b bioassay
Supernatants were obtained from con¯uent glioma cell cultures maintained in serum-free medium for 24 h. After harvest, the number of cells was obtained to determine TGF-b synthesis per cell. To determine TGF-b synthesis, 10,000 CCL64 cells per well were plated in 96 well plates in DMEM containing 1% penicilline/streptomycine and 50 mM mercaptoethanol, adhered for 24 h, and exposed to the glioma cell supernatants diluted 1 : 10. For the determination of total TGF-b, latent TGF-b was activated by transient acidi®cation. Diluted supernatants were acidi®ed for 1 h with 5N HCl and reneutralized by adding an equal volume of 5N NaOH and 1.25 volumes of 1 M sodium HEPES. After 24 h incubation, CCL64 cells were labeled with 3 H-thymidine (1 mCi/well) for 16 h, washed, and radioactivity incorporated into DNA determined in a liquid scintillation counter. Recombinant TGF-b 2 in logarithmic dilutions served as standard. TGF-b values are expressed as amount of TGF-b produced per 24 h per 10 6 cells.
Transfections
The p53ts val 135 hygro vector and a hygro control vector (p65) were kindly provided by MF Clarke (Pittsburgh, PA) (Ryan et al., 1994) . Transfection was carried out using electroporation (Biorad Gene Pulser, 250 V, 950 mF). Selection was started two days after transfection with hygromycin B for 6 ± 8 weeks (200 mg/ml).
Acridine orange nuclear staining
Multichamber glass slides were preincubated for 2 h with poly-L-lysine (25 mg/ml), washed twice with PBS, and 5610 4 cells seeded per chamber (Weller et al., 1994) . After 24 h, the cells were treated as indicated, ®xed using 3.7% formaldehyde diluted in PBS, and stained with acridine orange (1 mg/ml) in the presence of RNase A (100 mg/ml).
Flow cytometry analysis
10
6 cells were treated as indicated, trypsinized, centrifuged for 10 min at 48C, stained with FITC-labeled anti-CD95 antibody (UB2, Immunotech, Hamburg, Germany) or FITC-labeled mouse IgG (1 mg/ml) as a control, diluted in 100 ml PBS containing 1% bovine serum albumin and 0.01% sodium azide (¯ow cytometry buer), and incubated for 30 min at 48C. Thereafter, antibody was removed, cells washed twice in¯ow cytometry buer, and resuspended in 300 ml PBS containing 1% paraformaldehyde and stored light-protected at 48C until analysis in a FACScalibur (Beckton & Dickinson, Heidelberg, Germany). For¯ow cytometric cell cycle analysis, 0.5610 6 cells were washed, permeabilized with 75% ice-cold ethanol for 30 min and stained with propidium iodide for 30 min in the presence of RNase A (100 mg/ml). Measurements were performed using a Beckton & Dickinson FACScan using Cell Quest software.
Abbreviations CD95L, CD95 ligand; DEX, dexamethasone; IFN, interferon; IL-1b, interleukin-1b; iNOS, inducible NO synthase; L-NAME, L-nitro-arginine-methyl-ester; L-NMMA, L-N Gmonomethyl-L-arginine; NO, nitric oxide; LPS, lipopolysaccharide; SIN-1, 3-morpholinosydnonimine; SNP, sodium nitroprusside; TGF-b, transforming growth factorb; TNF, tumor necrosis factor.
